Core Viewpoint - A class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc., Bain Capital Investors, LLC, and Pfizer, Inc. for allegedly misleading investors regarding a secondary stock offering and the subsequent merger with AbbVie Inc. [1][2] Group 1: Allegations and Impact - The lawsuit claims that Cerevel's secondary offering documents omitted crucial information about AbbVie's interest in acquiring Cerevel at a significantly higher price than the offering price of $22.81 per share, which led to an artificially deflated stock price until the merger announcement [2] - Bain Capital, as Cerevel's controlling shareholder, allegedly purchased shares at this depressed price while possessing nonpublic information about AbbVie's acquisition interest, resulting in a profit exceeding $120 million when AbbVie announced the acquisition at $45 per share [2] - The action also seeks damages for investors who held shares as of January 8, 2024, due to misleading statements in Cerevel's January 18, 2024 Proxy statement regarding the nature and timing of AbbVie's interest [3] Group 2: Legal Proceedings - Shareholders interested in serving as lead plaintiffs must file their papers by June 3, 2025, to represent the class in the litigation [4] - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4] Group 3: Firm Background - Robbins LLP is noted for its focus on shareholder rights litigation, aiming to help shareholders recover losses and improve corporate governance since 2002 [5]

Core Viewpoint - The Schall Law Firm is investigating Cerevel Therapeutics Holdings, Inc. for potential violations of securities laws and breaches of fiduciary duty by its directors and management [1][2]. Group 1: Investigation Details - The investigation centers on whether Cerevel issued false or misleading statements and failed to disclose important information to investors [2]. - Cerevel was acquired by AbbVie Inc. on August 1, 2024, at a price of $45 per share [2]. Group 2: Legal Representation - The Schall Law Firm offers free consultations to shareholders who may have suffered losses and encourages them to discuss their rights [3]. - The firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally [3].

Core Viewpoint - Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. and AbbVie, Inc., raising concerns about the fairness of the transaction and the potential conflicts of interest among Cerevel's board of directors [4][5]. Group 1: Merger Details - On December 6, 2023, Cerevel Therapeutics announced its acquisition by AbbVie for $45.00 per share in cash, valuing the company at approximately $8.7 billion [8]. - The transaction has been approved by the boards of directors of both companies and is expected to close in mid-2024 [8]. Group 2: Legal Investigation - Bleichmar Fonti & Auld LLP believes that the board of directors of Cerevel Therapeutics was conflicted and engaged in an unfair process regarding the merger [5]. - Shareholders of Cerevel Therapeutics are encouraged to submit their information to explore their legal options related to the merger [6].

Core Viewpoint - Cerevel Therapeutics is set to be acquired by AbbVie for $45.00 per share, valuing the company at approximately $8.7 billion, with the transaction expected to close in mid-2024 [1] Group 1: Acquisition Details - AbbVie will acquire all outstanding shares of Cerevel Therapeutics for $45.00 per share in cash [1] - The total equity value of the transaction is approximately $8.7 billion [1] - The boards of directors of both companies have approved the transaction [1] Group 2: Legal Investigation - Bleichmar Fonti & Auld LLP is investigating the acquisition, alleging that Cerevel's board was conflicted and engaged in an unfair process [2][5] - Current shareholders of Cerevel are encouraged to submit their information to understand their rights regarding the transaction [2][3]

Core Viewpoint - The Schall Law Firm is investigating potential breaches of fiduciary duty by the board of Cerevel Therapeutics Holdings, Inc. towards its shareholders [1][3]. Group 1: Investigation Details - The investigation aims to determine if the Cerevel board has violated its fiduciary responsibilities to shareholders [1]. - The Schall Law Firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally [2][3]. Group 2: Contact Information - Investors can contact Brian Schall of the Schall Law Firm for discussions regarding their rights without any charge [4][6].

Core Viewpoint - Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics and AbbVie, raising concerns about the fairness of the transaction and the board's decision-making process [1][3]. Transaction Details - On December 6, 2023, Cerevel Therapeutics announced its acquisition by AbbVie for $45.00 per share in cash, valuing Cerevel at approximately $8.7 billion [2]. - The transaction has been approved by the boards of directors of both companies and is expected to close in mid-2024 [2]. Legal Investigation - Bleichmar Fonti & Auld LLP believes that the board of directors of Cerevel Therapeutics was conflicted and engaged in an unfair process regarding the acquisition [3]. - Current shareholders are encouraged to submit their information to understand their rights in this situation [3][4]. Law Firm Background - Bleichmar Fonti & Auld LLP is recognized as a leading international law firm specializing in securities class actions and shareholder litigation, having achieved significant recoveries in past cases [5].

Core Viewpoint - Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics and AbbVie, raising concerns about potential conflicts of interest and the fairness of the transaction [1][3]. Company Overview - Cerevel Therapeutics announced its acquisition by AbbVie on December 6, 2023, with AbbVie set to acquire all outstanding shares for $45.00 per share, valuing Cerevel at approximately $8.7 billion [4]. Legal Context - The law firm BFA believes that the board of directors of Cerevel Therapeutics was conflicted and engaged in an unfair process regarding the merger [1]. - Shareholders of Cerevel Therapeutics are encouraged to submit their information to explore their legal options [6]. Financial Implications - The transaction is expected to close in the middle of 2024, pending any legal challenges [4].

Core Viewpoint - Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics and AbbVie, focusing on potential conflicts and fairness in the transaction process [1][8]. Company Overview - Cerevel Therapeutics announced its acquisition by AbbVie on December 6, 2023, with AbbVie agreeing to pay $45.00 per share in cash, valuing Cerevel at approximately $8.7 billion [2]. Transaction Details - The acquisition has been approved by the boards of directors of both companies and is expected to close in mid-2024 [2]. Legal Investigation - Bleichmar Fonti & Auld LLP believes that the board of directors of Cerevel Therapeutics may have been conflicted and engaged in an unfair process regarding the acquisition terms [8]. - Current shareholders of Cerevel Therapeutics are encouraged to submit their information to explore their legal options [4][8]. Law Firm Background - Bleichmar Fonti & Auld LLP is recognized as a leading international law firm specializing in securities class actions and shareholder litigation, having achieved significant recoveries in past cases [7].

Core Viewpoint - Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics and AbbVie, focusing on potential conflicts and fairness of the transaction [1][7]. Group 1: Merger Details - Cerevel Therapeutics announced its acquisition by AbbVie on December 6, 2023, with AbbVie set to acquire all outstanding shares for $45.00 per share in cash [2]. - The total equity value of the transaction is approximately $8.7 billion, and it has been approved by the boards of directors of both companies [2]. Group 2: Legal Investigation - Bleichmar Fonti & Auld LLP believes that the board of directors of Cerevel Therapeutics was conflicted and engaged in an unfair process regarding the merger [7]. - Shareholders of Cerevel Therapeutics are encouraged to submit their information to explore their legal options [4][7]. Group 3: Law Firm Background - Bleichmar Fonti & Auld LLP is recognized as a leading international law firm specializing in securities class actions and shareholder litigation, having achieved significant recoveries in past cases [8].

Core Viewpoint - Cerevel Therapeutics is set to be acquired by AbbVie for $45.00 per share, valuing the company at approximately $8.7 billion, with the transaction expected to close in mid-2024 [1] Company Summary - AbbVie will acquire all outstanding shares of Cerevel Therapeutics for a cash price of $45.00 per share [1] - The total equity value of the transaction is around $8.7 billion [1] - The boards of directors of both companies have approved the acquisition [1] - The expected closing date for the transaction is in the middle of 2024 [1] Legal Investigation - Bleichmar Fonti & Auld LLP is investigating the merger, suggesting potential conflicts of interest within Cerevel Therapeutics' board of directors [9] - The law firm believes the process was unfair and the amount agreed upon for shareholders may also be unfair [9] - Current shareholders of Cerevel Therapeutics are encouraged to submit their information to understand their rights [9]